Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS? a meta-analysis of a first-generation vs. a second-generation drug-eluting stent system

Netherlands Heart Journal

Volumn 18, Issue 9, 2010, Pages 451-453

  Claessen, B E ^a   Stone, G W ^b   Smits, P C ^c   Kedhi, E ^c   Kikkert, W J ^a   Piek, J J ^a   Henriques, J P S ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NewYork Presbyterian Hospital   (United States)

^c Maasstad Hospital Rotterdam   (Netherlands)

Author keywords

Coronary Artery Bypass Surgery; Coronary Artery Disease; Drug Eluting Stents; Meta analysis; Percutaneous Coronary Intervention

Indexed keywords

EVEROLIMUS; PACLITAXEL;

ARTERY GRAFT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; RISK REDUCTION;

EID: 77956513678     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03091813     Document Type: Article

References (7)

1. Schatz RA, Palmaz JC, Tio FO, Garcia F, Garcia O, Reuter SR. Balloon-expandable intracoronary stents in the adult dog. Circulation. 1987;76:450-7.
2. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961-72.
3. Ruygrok PN, Desaga M, Van Den Branden F, Rasmussen K, Suryapranata H, Dorange C, et al. One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study. EuroIntervention. 2007;3:315-20.
4. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903-13.
5. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201-9.
6. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663-74.
7. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51.